Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 6/20 | 0.56 |
| ▸ | CNR2 | P34972 | 5/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL27555842 | 0.93 | MTNR1A (0.51) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL16197845 | 0.90 | MTNR1A (0.49) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL5846249 | 0.87 | KCNH2 (0.58) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL1321258 | 0.85 | MTNR1A (0.54) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL663798 | 0.84 | CNR1 (0.62) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| Hydrochloric Acid SCHEMBL5311014 | 0.84 | MTNR1A (0.53) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL16197842 | 0.83 | MTNR1A (0.46) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL11796932 | 0.81 | KCNH2 (0.76) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL181573 | 0.80 | GRIN1 (0.52) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL28309352 | 0.80 | CNR1 (0.47) | MTNR1AMTNR1BCNR1CNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1665 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1621546-B1 | Peptide ligands specific to immonoglobulins | TECNOGEN SPA (IT) | 2008-10-29 | — | — | EP | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| EP-1621546-A1 | Peptide ligands specific to immonoglobulins | TECNOGEN S.C.P.A. (IT) | 2006-02-01 | — | — | EP | claimed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12605425-B2 | TNF muteins and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-4710935-A2 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | Aravax Pty Ltd (AU) | 2026-03-18 | — | — | EP | disclosed |
| US-12576191-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2026-03-17 | — | — | US | disclosed |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| EP-3980085-B1 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | UNIV RAMOT (IL) | 2026-03-11 | — | — | EP | disclosed |
| WO-1997005257-A1 | PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| EP-0745092-A1 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5480871-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995027729-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0672049-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004072-A1 | PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1994028014-A2 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | MTNR1A 3312/4885MTNR1B 2815/4885CNR1 2624/4885 |
| US-12605425-B2 | TNF muteins and uses thereof | TNFRSF1A, TNF, TNFSF11 | MTNR1A 644/4885MTNR1B 1682/4885CNR1 3955/4885 |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CXCR4, CXCR2, GRPR | MTNR1A 407/4885MTNR1B 484/4885CNR1 216/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | MTNR1A 1691/4885MTNR1B 2335/4885CNR1 3712/4885 |
| US-12576191-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | MYLK2, TNNI3, MYL6 | MTNR1A 4133/4885MTNR1B 2634/4885CNR1 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.